Carbamazepine Chewable and Glecaprevir and pibrentasvir
Determining the interaction of Carbamazepine Chewable and Glecaprevir and pibrentasvir and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using glecaprevir together with carBAMazepine is not recommended. Combining these medications may significantly reduce the blood levels of both glecaprevir and pibrentasvir, the active components of your hepatitis C medication. This may make the medication less effective in treating your infection. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent inducers of P-glycoprotein (P-gp) or CYP450 3A4 may significantly decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral agents are substrates of the P-gp efflux transporter, and glecaprevir is additionally a substrate of the CYP450 3A4 isoenzyme. When a single 300 mg-120 mg dose of glecaprevir-pibrentasvir was administered to 12 study subjects following multiple dosing of the potent inducer rifampin at 600 mg once daily, glecaprevir peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 86% and 88%, respectively, while pibrentasvir Cmax and AUC decreased by 83% and 87%, respectively. Likewise, when a single dose of glecaprevir-pibrentasvir was administered to 10 study subjects following multiple dosing of carbamazepine 200 mg twice daily, glecaprevir Cmax and AUC decreased by approximately two-thirds, while pibrentasvir Cmax and AUC decreased by approximately one-half.
MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of glecaprevir and pibrentasvir with potent P-gp or CYP450 3A4 inducers is not recommended.
- "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: carbamazepine
Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR
Synonyms: Carbamazepine, CarBAMazepine
Generic Name: glecaprevir / pibrentasvir
Brand name: Mavyret
Synonyms: Glecaprevir and Pibrentasvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Carbamazepine Chewable-Gleevec
- Carbamazepine Chewable-Glenmax PEB DM
- Carbamazepine Chewable-Glenmax PEB DM FORTE
- Carbamazepine Chewable-Gleolan
- Carbamazepine Chewable-Gleostine
- Carbamazepine Chewable-Gliadel
- Glecaprevir and pibrentasvir-Carbamazepine Chewable Tablets
- Glecaprevir and pibrentasvir-Carbamazepine ER
- Glecaprevir and pibrentasvir-Carbamazepine Extended-Release Capsules (Carbatrol)
- Glecaprevir and pibrentasvir-Carbamazepine Extended-Release Capsules (Equetro)
- Glecaprevir and pibrentasvir-Carbamazepine Extended-Release Tablets
- Glecaprevir and pibrentasvir-Carbamazepine Intravenous